Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT02464657 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Nivolumab
DRUG: Idarubicin
DRUG: Cytarabine
DRUG: Solu-medrol
DRUG: Dexamethasone

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]